Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: A pilot clinical study

References

• Walsh M C, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003; 23: 451–456
   PubMedGoogle Scholar
• Speer C P, Groneck P. Oxygen radicals, cytokines, adhesion molecules and lung injury in neonates. Semin Neonatol 1998; 3: 219–228
   Google Scholar
• Speer C P. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79: 205–209
   PubMedGoogle Scholar
• Zimmermann J J. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin Perinatol 1995; 22: 429–456
   PubMed Web of Science ®Google Scholar
• Halliday H L, Ehrenkranz R A. Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 1 2000, CD001144
   Google Scholar
• Halliday H L, Ehrenkranz R A. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2 2000, CD001969
   Google Scholar
• Halliday H L, Ehrenkranz R A. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Sys Rev 2 2001, CD001145
   Google Scholar
• Raju N V, Bharadwaj R A, Thomas R, Konduri G G. Ibuprofen use to reduce the incidence and severity of bronchopulmonary dysplasia: A pilot study. J Perinatol 2000; 20: 13–16
   PubMedGoogle Scholar
• Viscardi R M, Hasday J D, Gumper K F, Campbell A B, Palmer T W. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997; 156: 1523–1529
   PubMed Web of Science ®Google Scholar
• Currie M S, Rao K M, Padmanabhan J, Jonas A, Crawford J, Cohen H J. Stimulus specific effects of pentoxifylline on neutrophils CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990; 47: 244–250
   PubMed Web of Science ®Google Scholar
• Roberts P J, Yog K L, Khwaja A, Johnson B V, Pizzey A R, Carver J E, Addisson I E, Linch D C. Pentoxifylline at clinically achievable levels inhibits FMLP induced neutrophil responses, but not priming, upregulation, cell-adhesion molecules, or emigration induced by GM-CSF. Eur J Haemat 1993; 22: 371–382
   Google Scholar
• Marques L J, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am J Resp Crit Care Med 1999; 159: 508–511
   PubMed Web of Science ®Google Scholar
• Poulakis N, Androutsos G, Kazi D, Bastas A, Provata A, Bitsakou C, Kontozoglou T, Polyzogopoulou C, Tassiapoulou A. The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications. Resp Med 1999; 93: 52–57
   PubMed Web of Science ®Google Scholar
• Little S, Dean T, Bevin S, Hall M, Ashton M, Chruch M, Warner J, Shute J. Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants. Thorax 1995; 50: 1073–1079
   PubMed Web of Science ®Google Scholar
• Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumor necrosis factor-α concentration in premature infants with sepsis. Eur J Pediatr 1996; 155: 404–409
   PubMed Web of Science ®Google Scholar
• Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med 1999; 27: 807–814
   PubMed Web of Science ®Google Scholar
• Lauterbach R, Szymura-Oleksiak J. Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr 1999; 158: 607
   PubMed Web of Science ®Google Scholar
• Brozanski B S, Jones J G, Gilmour C H, Balsan M J, Vazquez R L, Israel B A, Newman B, Mimouni F B, Guthrie R D. Effects of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infants. J Pediatr 1995; 126: 769–776
   PubMed Web of Science ®Google Scholar
• Mancinelli A, Pace S, Marzo A, Martelli E A, Passetti G. Determination of pentoxifylline and its metabolites in human plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 1992; 575: 101–107
   PubMed Web of Science ®Google Scholar
• Papile L A, Munsick-Bruno G, Schaefer A. Relationship of cerebral intraventricular hemorrhage and early childhood neurologic handicaps. J Pediatr 1983; 103: 273–277
   PubMed Web of Science ®Google Scholar
• Cordero L, Ayers L W, Barns K. Neonatal airways colonization with Gram-negative bacilli: Association with severity of bronchopulmonary dysplasia. Pediatr Infect Dis J 1997; 16: 18–23
   PubMed Web of Science ®Google Scholar
• Groneck P, Gotze-Speer B, Speer C P. Inflammatory bronchopulmonary response of preterm infants with microbial colonization of the alveolar at birth. Arch Dis Child 1996; 74: F51
   Web of Science ®Google Scholar
• Szymura-Oleksiak J, Bury J, Lauterbach R, Pawlowski M. Serum concentrations of pentoxifylline and its metabolites in premature infants with sepsis when administered by continuous intravenous infusion. Pharm Sci 1997; 3: 1–5
   Google Scholar
• Oliveira-Junior I S, Pinheiro B V, Silva I D, Salomao R, Zollner R L, Beppu O S. Pentoxifylline decreases tumor necrosis factor and interleukin-1 during high tidal volume. Brazil J Med Biol Res 2003; 36: 1349–1357
   PubMed Web of Science ®Google Scholar